November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which demonstrated the long-term efficacy and safety of the Axxess stent for patients with coronary bifurcation lesions. The device is a self-expanding bifurcation stent that releases Biolimus A9 from an abluminal biodegradable polymer coating.

Medtronic today announced it received CE (Conformité Européenne) mark for the CoreValve System to be delivered using direct aortic access. The Medtronic CoreValve System is now the only transcatheter aortic valve implantation (TAVI) system approved for direct aortic and subclavian implantation.

November 8, 2011 – Abiomed, a provider of heart support technologies, announced results of an economic study at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) conference. The economic study demonstrated that Impella significantly reduced major adverse events at an incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies.  Quality of life benefits included an increase in ejection fraction of over 20 percent and an improvement in New York Heart Association (NYHA) Class III and Class IV heart failure of over 50 percent.

November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the Promus Element everolimus-eluting platinum chromium (PtCr) stent system in patients with long coronary lesions.  Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, Calif., and co-principal investigator of the trial, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now